March 24th 2024
For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
More CV, Renal Outcomes at ADA: CREDENCE, CARMELINA, CAROLINA
June 12th 2019The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
Read More
Highlighting Links Between Kidney, CV Disease in Diabetes
June 11th 2019The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
Read More
This Week in Managed Care: May 31, 2019
May 31st 2019This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
Watch
A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with standard treatment using sulfonylurea and insulin for patients with type 2 diabetes who have difficulty maintaining glycated hemoglobin of seven percent or less on metformin alone.
Read More
As Comorbidities Pile Up, True Diabetes Cost Measured by More Than Insulin, Panel Says
April 14th 2019For endocrinologists, a cardiologist, a diabetes educator, and a room full of fellow health workers, the cost of doing nothing—not just to treat diabetes, but also to prevent it— is what feeds into the exorbitant cost of the disease, according to presentations and a panel at the inaugural meeting of the Institute for Value Based Medicine (IVBM) in Diabetes, an initiative of The American Journal of Managed Care®.
Read More
Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population
April 8th 2019Previous research overstated the generalizability of the Exenatide Study of Cardiovascular Event Lowering trial results by omitting the restriction on the percentage of patients without a prior cardiovascular event.
Read More
Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”
The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
Read More
Amarin Files Supplemental NDA With FDA for Vascepa Based on REDUCE-IT Results
April 4th 2019Based on recently published results of the REDUCE-IT study, pharmacuetical company Amarin has submitted a supplemental new drug application (sNDA) to the FDA for an expanded label for its leading drug Vascepa. Also, the American Diabetes Association has included the drug in a mid-year update to its 2019 Standards of Medical Care in Diabetes.
Read More
5 Takeaways From the 2019 American College of Cardiology Meeting
March 22nd 2019For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.
Read More
Amarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study
March 18th 2019New results presented at the American College of Cardiology's 68th Annual Scientific Session find a high-dose fish oil pill reduced the risk for first and future cardiovascular events among patients taking statins by 30%. The early results grabbed headlines last fall in part because researchers aren't entirely sure how the capsule works.
Read More
DECLARE: Dapagliflozin Offers Benefits for Diabetes Patients With Heart Failure
March 18th 2019New findings show reduced hospitalizations for a wide group of patients with heart failure. For high-risk patients with reduced ejection fraction, the drug appears to cut deaths, but more studies will answer these questions.
Read More
Cardiovascular Prevention Guidelines Call for Less Aspirin, More SGLT2s, GLP-1s for Type 2 Diabetes
March 17th 2019The joint guidelines from the American College of Cardiology and the American Heart Association call on clinicians to pay more attention to social determinants of health. They were announced Sunday at the 68th Scientific Session of the American College of Cardiology in New Orleans, Louisiana.
Read More
Giant Study Suggests Apple Watch Accurately Catches Atrial Fibrillation
March 16th 2019The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.
Read More
From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting
March 16th 2019In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.
Read More
What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue
February 28th 2019Researchers have confirmed that there is no link between flu shots and miscarriages; a liquid biopsy is as effective as tissue-based testing for identifying treatment for lung cancer; and physicians generate an average of $2 million a year for hospitals.
Read More
Even Among the Insured, Patients With Cardiovascular Disease Face Financial Toxicity
February 13th 2019Atherosclerotic cardiovascular disease (ASCVD) is not only a leading cause of mortality among US adults, but also responsible for high medical costs that burden both the healthcare system and individual patients. New research shows that 1 in every 5 patients with ASCVD is unable to afford his or her medical bills, and even among patients with insurance, financial hardship related to medical costs is prevalent.
Read More
2018 American College of Cardiology ECDP Encourages Collaboration Among Specialists and PCPs
February 7th 2019The American Journal of Managed Care® (AJMC®) recently spoke with Om P. Ganda, MD, medical director of the Lipid Clinic and chair of the Clinical Oversight Committee at the Joslin Diabetes Center in Boston, Massachusetts, about the recent publication of the 2018 American College of Cardiology (ACC) Expert Consensus Decision Pathway (ECDP).1
Read More
Javed Butler, MD, MPH, MBA, discusses the 2018 American College of Cardiology Expert Consensus Decision Pathway, which includes guidance on the use of SGLT2 inhibitors and GLP-1 receptor agonists, and its potential to change the treatment paradigm for patients with type 2 diabetes.
Read More
Alzheimer's Association Funds Extension of Study on Blood Pressure, Dementia Connection
January 29th 2019The National Institutes of Health halted the landmark SPRINT study in 2015 after results clearly showed a cardiovascular benefit for patients who had their systolic blood pressure aggressively controlled to 120 mm/Hg.
Read More